Benefits
Biological age reduction (Demidenko 2021 — small study)
Demidenko 2021 (PMC8660611) longitudinal observational study followed 42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG + sex-specific vitamins) for 4-10 months. AVERAGE 8-YEAR REDUCTION in biological age (TruAge DNA methylation test) over 7 months. Substantial effect size if real. CRITICAL CAVEATS: (1) self-reported, no placebo control, (2) single DNA methylation clock used, (3) selection bias possible, (4) small sample (n=42), (5) Ca-AKG combined with vitamins (cannot attribute to AKG alone). Hypothesis-generating, not confirmatory.
ABLE Phase 2 RCT ongoing
ABLE trial (NCT05706389, National University of Singapore Phase 2 RCT) testing Ca-AKG vs placebo for 6 months in 120 middle-aged adults (40-60 years) with biological age higher than chronological age. Primary outcome: biological age change. Will provide more rigorous evidence than Rejuvant observational study. Ongoing — results pending. Critical for definitively establishing or refuting biological age effects.
Animal lifespan extension across multiple species
AKG extends lifespan in fruit flies, C. elegans roundworms, and mice. Asadi Shahmirzadi 2020 mouse study showed Ca-AKG reduced frailty and enhanced longevity (compression of morbidity). Mechanism: caloric restriction mimetic via inhibiting ATP synthase and TOR, activating AMPK. Foundational preclinical evidence supporting human longevity research interest.
Bone density and strength support
Animal studies and limited human evidence suggest Ca-AKG supports bone density. Mechanism: stimulates collagen synthesis (proline hydroxylation requires AKG cofactor) and provides calcium for mineralization. Some human RCTs in osteoporosis showed bone marker improvements. Useful potential adjunct for skeletal health, particularly in older adults.
Wound healing and protein synthesis
Older clinical research showed AKG (often as ornithine α-ketoglutarate, OKG) improves nitrogen balance in surgical patients and burn victims. Improves wound healing and reduces protein catabolism. Mechanism via amino acid synthesis support and growth hormone secretion. Clinical use in some European hospitals as nutritional adjunct.
Muscle protein synthesis support (preclinical)
AKG provides nitrogen carriers for amino acid synthesis (transamination reactions), supporting muscle protein synthesis and reducing protein catabolism in stress states. Animal evidence supports anabolic effects; human translation in athletic/aging contexts is incomplete.
Mechanism of action
TCA cycle intermediate (energy metabolism)
AKG is one of eight TCA cycle intermediates — converted to succinyl-CoA via α-ketoglutarate dehydrogenase. Critical for glucose, fatty acid, and amino acid oxidation. Energy production substrate. Provides direct metabolic support for cellular energy demands.
Substrate for dioxygenases (epigenetic regulation)
AKG is required cofactor for 2-OG-dependent DIOXYGENASES — including TET enzymes (DNA demethylation), JmjC histone demethylases (chromatin modification), prolyl hydroxylases (collagen synthesis, HIF regulation), and many others. Supplementation may support epigenetic regulation — mechanism for biological age effects observed in Demidenko 2021.
Caloric restriction mimetic via ATP synthase / TOR / AMPK
Animal studies show AKG inhibits ATP synthase and TOR (target of rapamycin) signaling while activating AMPK pathway — mimicking effects of caloric restriction (the most reliable known longevity intervention in animals). Mechanism for lifespan extension observed in flies, worms, mice.
Glutamate-glutamine cycling and nitrogen metabolism
AKG combines with ammonia via glutamate dehydrogenase to form glutamate — central nitrogen disposal pathway. Used clinically (post-surgery) to manage nitrogen balance and support amino acid synthesis. Mechanism for protein-anabolic effects in catabolic states.
Calcium delivery (Ca-AKG specifically)
Ca-AKG salt provides BOTH alpha-ketoglutarate AND calcium — useful for bone health and as practical delivery mechanism. Calcium AKG enhances oral stability and bioavailability vs free AKG. Bone density benefits may relate to combined AKG + calcium effects rather than AKG alone.
Clinical trials
Longitudinal observational study (Demidenko O, Barardo D, Budovskii V, Finnemore R, Palmer FR 3rd, Kennedy BK, Budovskaya YV 2021, Aging 13(22):24485-24499, doi:10.18632/aging.203736, PMID 34847777). PMC8660611.
42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG + sex-specific vitamins) for 4-10 months. Biological age measured by TruAge DNA methylation test (Horvath-derived clock) before/during/after treatment.
Average 8-YEAR REDUCTION in biological age (TruAge DNA methylation) over average 7 months Rejuvant supplementation. Substantial effect if real. CRITICAL CAVEATS: (1) observational/uncontrolled design, no placebo, (2) self-reported subjects with potential selection bias, (3) single DNA methylation clock, (4) Rejuvant is combination product (AKG + vitamins), (5) sponsored by Ponce de Leon Health (commercial interest), (6) small sample. Most-cited human evidence for AKG biological age effects but methodologically limited.
Mouse longevity study (Asadi Shahmirzadi A, Edgar D, Liao CY, Hsu YM, Lucanic M, Asadi Shahmirzadi A, Wiley CD, Gan G, Kim DE, Kasler HG, Kuehnemann C, Kaplowitz B, Bhaumik D, Riley RR, Kennedy BK, Lithgow GJ 2020, Cell Metab 32(3):447-456.e6, doi:10.1016/j.cmet.2020.08.004).
C57BL/6 mice received Ca-AKG supplementation. Frailty, lifespan, and healthspan measured.
Ca-AKG REDUCED frailty and ENHANCED LONGEVITY in mice — compression of morbidity (mice lived longer AND with less age-related decline). Mechanism via inflammation reduction (reduced IL-6, IL-10) and improved healthspan markers. Foundational animal evidence supporting Ca-AKG's emergence as 'longevity supplement.' Critical mouse-to-human translation gap — animal lifespan studies do not reliably predict human supplementation effects.
Phase 2 randomized double-blind placebo-controlled trial (NCT05706389). National University of Singapore.
120 healthy middle-aged adults (40-60 years) with biological age higher than chronological age. Randomized to Ca-AKG or placebo for 6 months. Primary outcome: biological age change.
Currently ONGOING. Will provide more rigorous evidence than Demidenko 2021 observational study. Critical trial for the field — randomized placebo-controlled design with adequate sample size to detect biological age effects. Results pending. Independent of commercial Rejuvant sponsor. Important for definitively establishing or refuting Ca-AKG biological age effects.
About this ingredient
Alpha-ketoglutarate (α-KG, 2-oxoglutarate, AKG) is a 5-carbon dicarboxylic acid that is one of the most metabolically central molecules in cells — functioning as: (1) TCA CYCLE INTERMEDIATE (8 of 8 cycle intermediates), (2) UNIVERSAL COFACTOR for 2-oxoglutarate-dependent dioxygenases (60+ enzymes including TET DNA demethylases, JmjC histone demethylases, prolyl hydroxylases, asparaginyl hydroxylases), (3) NITROGEN CARRIER via glutamate-glutamine cycling, (4) AMINO ACID PRECURSOR (glutamate, glutamine, proline, arginine biosynthesis). Endogenously produced in every cell. Free AKG has poor oral bioavailability (half-life <5 minutes; ~40% intestinal absorption) — necessitating stabilized salt forms for supplementation.
CALCIUM ALPHA-KETOGLUTARATE (Ca-AKG) is the most-studied supplement form — provides ~10-15% calcium by weight along with stabilized AKG delivery. Other forms: ornithine alpha-ketoglutarate (OKG) used in clinical surgical/burn nutrition; ammonium AKG used in research. Background research interest accelerated with Asadi Shahmirzadi 2020 mouse study showing Ca-AKG reduced frailty and enhanced longevity in C57BL/6 mice.
AKG-containing supplements (Rejuvant by Ponce de Leon Health, generic Ca-AKG products) have grown significantly in longevity supplement market. EPIGENETIC ANGLE: AKG is required cofactor for TET enzymes (5-mC oxidation/DNA demethylation) and JmjC histone demethylases — providing biochemical basis for hypothesis that AKG supplementation could modulate epigenetic age. Demidenko 2021 study reported large biological age reductions, driving substantial interest.
EVIDENCE: 2/5 reflects: (1) Demidenko 2021 PMC8660611 observational Rejuvant study with substantial biological age effects but major methodological limitations, (2) Asadi Shahmirzadi 2020 mouse longevity foundational evidence, (3) ABLE Phase 2 RCT ongoing — critical confirmatory trial, (4) older clinical use in surgical nutrition (OKG), (5) emerging bone health evidence with Ca-AKG, (6) clear biochemical mechanism. LIMITED BY: only one published human biological age study (uncontrolled, sponsored, small); animal-to-human translation uncertain; ABLE trial not yet complete. SAFETY: Excellent at typical supplement doses; calcium content of Ca-AKG warrants attention in hypercalcemia or kidney stone history.
Best positioned as: (a) LONGEVITY/HEALTHSPAN SUPPLEMENT for those interested in epigenetic age modulation (with appropriate epistemic humility about evidence quality), (b) BONE HEALTH adjunct (calcium delivery + AKG mechanisms), (c) MITOCHONDRIAL/ENERGY SUPPORT via TCA cycle intermediate provision, (d) MUSCLE PROTEIN/RECOVERY in catabolic states (older clinical evidence with OKG), (e) NOT a confirmed longevity treatment — wait for ABLE trial results before strong claims, (f) reasonable adjunct in comprehensive longevity stack, (g) Ca-AKG salt preferred over free AKG. Honest framing: alpha-ketoglutarate is biochemically central and mechanistically compelling for longevity — animal lifespan evidence is solid and the Demidenko 2021 human biological age data is intriguing. However, the human evidence base is dominated by ONE observational study (commercially sponsored), and the field awaits the ABLE Phase 2 RCT for rigorous confirmation.
Reasonable longevity supplement to consider with appropriate evidence-based caution; not a confirmed intervention.